Evidence map›Paper›PMID 32267348›Full record

Trial reportArchives of endocrinology and metabolism2020

Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study.

Valentina K Bayrasheva, Ivan Y Pchelin, Vladimir A Dobronravov, Alina Yu Babenko, Svetlana G Chefu, Ivan S Shatalov, Volha N Vasilkova, Natalia V Hudiakova, Alexandra N Ivanova, Pavel A Andoskin and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Valentina K BayrashevaInstitute of Endocrinology, Almazov National Medical Research Centre, Saint Petersburg, Russia.
Ivan Y PchelinDepartment of Faculty Therapy, Saint Petersburg State University,, Saint Petersburg, Russia.
Vladimir A DobronravovResearch Institute of Nephrology, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.
Alina Yu BabenkoInstitute of Endocrinology, Almazov National Medical Research Centre, Saint Petersburg, Russia.
Svetlana G ChefuExperimental Research Laboratory, Laser Medicine Center, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.
Ivan S ShatalovScientific and Research Institute of Bioengineering, Saint Petersburg National Research University of Information, Technologies, Mechanics and Optics, Saint Petersburg, Russia.
Volha N VasilkovaDepartment of Internal Medicine No.1 with the Course of Endocrinology, Gomel State Medical University, Gomel, Belarus.
Natalia V HudiakovaDepartment of Faculty Therapy, Saint Petersburg State University,, Saint Petersburg, Russia.
Alexandra N IvanovaDepartment of Faculty Therapy, Saint Petersburg State University,, Saint Petersburg, Russia.
Pavel A AndoskinLaboratory of Protein Biochemistry, State Research Institute of Highly Pure BioSubstances, Saint Petersburg, Russia.
Elena N GrinevaInstitute of Endocrinology, Almazov National Medical Research Centre, Saint Petersburg, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective The aim of this randomized comparative study was to assess renal and metabolic effects of vildagliptin in insulin-treated type 2 diabetes (T2DM) patients without overt chronic kidney disease. Subjects and methods We randomized 47 insulin-treated non-proteinuric patients with satisfactory controlled T2DM and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m 2 either to continue insulin therapy (control) or to receive combined insulin-vildagliptin treatment (VIG group). We assessed eGFR using serum creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys), and urinary creatinine-adjusted excretion of albumin (UACR), type IV collagen (uCol IV/Cr), and neutrophil gelatinase-associated lipocalin (uNGAL/Cr) at baseline and after 6 months of treatment. Results Study groups were comparable in terms of age and sex (60.1 ± 6.1 years and 42.9% men in control group vs. 60.8 ± 5.2 years and 39.1% in VIG group). After 6 months of treatment, there were no significant changes in main assessed parameters in control group. VIG group demonstrated significant decrease in HbA1c, diastolic blood pressure, frequency of hypoglycemia, and high-sensitivity C-reactive protein level as compared to the changes in control group. While eGFRcreat, UACR, and uNGAL/Cr showed no significant changes after vildagliptin addition, eGFRcys, eGFRcreat-cys, and uCol IV/Cr changed significantly in comparison with control group (+7.0% [3.7;13.3]; +5.1% [1.4;8.5]; -32,8% [-55.8;-24.4], respectively, p < 0.01 each). Correlation and regression analysis revealed glucose-independent pattern of these changes. Conclusion Addition of vildagliptin to ongoing insulin therapy in patients with T2DM was associated with a reduction in uCol IV/Cr and an increase in eGFRcys and eGFRcreat-cys, independent of T2DM control parameters.

Indexed as

Diabetes Mellitus, Type 2AgedFemaleHumansHypoglycemic AgentsInsulinKidneyMaleMiddle AgedProspective StudiesVildagliptinHypoglycemic AgentsInsulinVildagliptin

Identifiers

PMID32267348
PMCPMC10522081

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.